Lonza Group Ltd., one of the world’s top suppliers of drug ingredients to pharmaceutical companies, announced on Monday that it will pay $1.2 billion to acquire Arch Chemicals, Inc.

Arch makes microbe-killing chemicals for use in water, wood, and consumer products, a business Lonza is trying to build. Lonza, of Basel, Switzerland, agreed to pay $47.20 a share for Arch, a 36 percent premium over the target’s average closing price from the past month. The acquisition, which is subject to shareholder and regulatory backing, is expected to close later this year.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]